Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans considers REA a BUY.
Michael Gable, Managing Director of Fairmont Equities, shares his view with you on Macquarie Group (MQG).
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans regards ResMed (RMD) as a BUY.
Michael Gable, Managing Director of Fairmont Equities, explains why Arafura Rare Earths (ARU) is potentially a higher risk/reward way for investors to gain exposure to the rare earth market.
Raymond Chan, private client adviser and head of Asian Desk, notes that Morgans has a BUY rating on Newmont Corporation (NEM).
Michael Gable, Managing Director of Fairmont Equities, explains why he's confident that South32 (S32) is getting close to breaking out of this consolidation and rallying strongly once more.
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans has Elders Limited (ELD) as a BUY on its Best Ideas List.
Michael Gable, Managing Director of Fairmont Equities, explains why Mineral Resources (MIN) is a buy for those investors looking to get in early.
Raymond Chan comments that Morgans has updated its recommendation for Sigma Healthcare (SIG) from ACCUMULATE to BUY.
In our “HOT” stock article, Michael Gable, Managing Director of Fairmont Equities, says that Iluka Resources (ILU) shares should be ready now to push higher […]
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.